Findings may help with decision-making in this high-risk patient population.
The patients, a 71-year-old male and a 62 year-old-male, both on long-term warfarin therapy, presented to the emergency department with symptoms of COVID-19.
Drugs in the Pipeline
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.
The patient developed a generalized maculopapular rash approximately 3 hours after receiving warfarin.